Top

Published in:

06-02-2024 | Atrial Fibrillation | Invited Editorial

Dapagliflozin for Atrial Fibrillation

Authors: Na Li, Mihail G. Chelu, Yochai Birnbaum

Published in: Cardiovascular Drugs and Therapy | Issue 1/2024

Excerpt

Sodium glucose cotransporter-2 (SGLT2) inhibitors, originally developed for the treatment of type-2 diabetes, have shown efficacy in improving cardiovascular outcomes in patients with heart failure (both in heart failure with reduced and preserved ejection fraction), with and without diabetes. Additional evidence has been accumulating on the favorable effects of SGLT2 inhibitors in other cardiovascular pathologies. …

Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227–34. https://doi.org/10.1161/CIRCULATIONAHA.119.044183.CrossRefPubMed

Luo F, Sun L, Wang Z, et al. Effect of dapagliflozin on the outcome of radiofrequency catheter ablation in patients with type 2 diabetes mellitus and atrial fibrillation. Cardiovasc Drugs Ther. 2024;38(1). https://doi.org/10.1007/s10557-022-07368-2.

Kishima H, Mine T, Fukuhara E, et al. Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393–404. https://doi.org/10.1016/j.jacep.2022.08.004.CrossRefPubMed

Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol. 2023;9(10):2109–18. https://doi.org/10.1016/j.jacep.2023.06.008.CrossRefPubMed

Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119–32. https://doi.org/10.1007/s10557-017-6725-2.CrossRefPubMed

Ryaboshapkina M, Ye R, Ye Y, Birnbaum Y. Effects of dapagliflozin on myocardial gene expression in BTBR mice with type 2 diabetes. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07517-1.CrossRefPubMed

Scisciola L, Chianese U, Caponigro V, et al. Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes. J Transl Med. 2023;21(1):662. https://doi.org/10.1186/s12967-023-04537-1.CrossRefPubMedPubMedCentral

Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates Na(+)/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553–8. https://doi.org/10.1007/s10557-018-6837-3.CrossRefPubMed

Wang X, Chen X, Dobrev D, Li N. The crosstalk between cardiomyocyte calcium and inflammasome signaling pathways in atrial fibrillation. Pflugers Arch. 2021;473(3):389–405. https://doi.org/10.1007/s00424-021-02515-4.CrossRefPubMedPubMedCentral

10.

Hui Y, Junzhu C, Jianhua Z. Gap junction and Na+-H+ exchanger alternations in fibrillating and failing atrium. Int J Cardiol. 2008;128(1):147–9.CrossRefPubMed

11.

Jayachandran JV, Zipes DP, Weksler J, Olgin JE. Role of the Na(+)/H(+) exchanger in short-term atrial electrophysiological remodeling. Circulation. 2000;101(15):1861–6. https://doi.org/10.1161/01.cir.101.15.1861.CrossRefPubMed

12.

Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114(1):12–8. https://doi.org/10.1093/cvr/cvx149.CrossRefPubMed

13.

Gao J, Xue G, Zhan G, et al. Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. 2022;9:1011429. https://doi.org/10.3389/fcvm.2022.1011429.CrossRefPubMedPubMedCentral

14.

Peng X, Li L, Zhang M, et al. Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction. Front Physiol. 2020;11:912. https://doi.org/10.3389/fphys.2020.00912.CrossRefPubMedPubMedCentral

15.

Lee K, Lee SK, Lee J, et al. Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus. PLoS One. 2023;18(1):e0280359. https://doi.org/10.1371/journal.pone.0280359.CrossRefPubMedPubMedCentral

Title: Dapagliflozin for Atrial Fibrillation
Authors: Na Li
Mihail G. Chelu
Yochai Birnbaum
Publication date: 06-02-2024
Publisher: Springer US
Keywords: Atrial Fibrillation
Dapagliflozin
Published in: Cardiovascular Drugs and Therapy / Issue 1/2024
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-024-07543-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dapagliflozin for Atrial Fibrillation

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

P2Y12 Inhibitors in STEMI Patients — One Size Does Not Fit All

The Effect of Colchicine in Acute Myocardial Infarction

Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis

Therapeutic Strategies Targeting Mitochondrial Dysfunction in Sepsis-induced Cardiomyopathy

Comment on “Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients”

Differential Proteomic Profiles of Coronary Serum Exosomes in Acute Myocardial Infarction Patients with or Without Diabetes Mellitus: ANGPTL6 Accelerates Regeneration of Endothelial Cells Treated with Rapamycin via MAPK Pathways

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page